Pay in 4 interest-free payments of $7.21 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
We should not look at these medications as weak or strong, but consider the needs of each patient individually, she says
Further randomized controlled trials and long-term observational studies are needed to validate its efficacy and safety profile
Because GLP-2 acts through subepithelial myofibroblasts, which are the same cell population implicated in intestinal fibrogenesis, the risk-benefit profile of GLP-2 agonism may differ substantially between mucosal UC, inflammatory ileal CD, and stricturing or penetrating CD phenotypes, and this phenotypic stratification should be a required feature of future trial design
Feng H, Tian C, Jiang W, Sun Z, Li Y, Han B, et al
Kang, D.H., Kwon, S.H., Sim, W.Y., Lew, B.L., (2024)
US$ 28.92
US$ 23.46
US$ 22.72
US$ 22.91
